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Abstract
A 3-month-old male intact Shiba Inu dog was evaluated for a seizure disorder initially
deemed idiopathic in origin. Seizure frequency remained unchanged despite thera-
peutic serum phenobarbital concentration and use of levetiracetam. The dog was
documented to be markedly hypoglycemic during a seizure episode on reevaluation
at 6 months of age. Serum insulin concentrations during hypoglycemia were 41 U/μL
(reference range, 10-29 U/μL). The dog was transitioned to 4 times per day feeding,
diazoxide was started at 3.5 mg/kg PO q8h, and antiepileptic drugs were discon-
tinued. No clinically relevant abnormalities were identified on bicavitary arterial and
venous phase contrast computed tomographic imaging. The dog remained seizure-
free and clinically normal at 3 years of age while receiving 5.5 mg/kg
diazoxide PO q12h and twice daily feeding. Seizures later occurred approximately
twice per year and after exertion, with or without vomiting of a diazoxide dose.
Blood glucose curves and interstitial glucose monitoring were used to titrate
diazoxide dose and dosing interval. Congenital hyperinsulinism is well recognized in
people but has not been reported in veterinary medicine.
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1 | CASE DESCRIPTION
A 3-month-old intact male Shiba Inu was presented for evaluation of
seizure episodes. Seizures involved focal symmetrical facial and auric-
ular twitching and tonic episodes affecting all 4 limbs with
opisthotonos, urination and defecation, and progression to general-
ized tonic-clonic seizures. The dog often was normal by the time of
examination but was reported to be lethargic after seizures for several
minutes. These events occurred once weekly and lasted from 1 to
30 minutes. Episodes tended to occur in the early hours of the morn-
ing. General physical examination was unremarkable and the dog
appeared to be growing appropriately. Neurological examination was
unremarkable except for occasional aggressive behavior. The history
of seizures was considered consistent with a forebrain neuroanatomi-
cal localization.
Investigations during 3 visits over the course of 10 days docu-
mented both normoglycemia (77 mg/dL [Vetscan VS2, Abaxis; refer-
ence range, 59-110 mg/dL; visit 2] and 81 mg/dL [Alphatrack 2,
Zoetis; visit 2]) and borderline or actual hypoglycemia with recordings
of 68 mg/dL (Alphatrack 2, visit 1), 65 mg/dL (Radiometer ABL 800
Flex; reference range, 76-119 mg/dL; visit 3), and 49 mg/dL (VetScan
VS2; reference range, 59-110 mg/dL; visit 1). Plasma ammonia con-
centration was 15 μM/L (reference range, 0-99 μM/L). Blood gas anal-
ysis, hematology, and serum biochemistry results were otherwise
normal. Serum cholesterol concentration was 5.42 mM/L (reference
range, 3.2-6.2 mM/L) and although serum triglyceride concentrationAbbreviations: CHI, congenital hyperinsulinism; IGF, insulin-like growth factor.
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was not measured, lipemic serum was not reported. Bile acid stimula-
tion testing was normal (preprandial, 1.9 μM/L; reference range, 0-
25 μM/L; postprandial, 5.1 μM/L; reference range, 0-40 μM/L) and
serology testing for Toxoplasma gondii and Neospora caninum was neg-
ative. Urine specific gravity was 1.029, no glucosuria was detected,
and sediment examination was normal. Urine culture was not
performed.
Borderline hypoglycemia was thought to represent juvenile
fasting hypoglycemia. The dog was anesthetized and high-field mag-
netic resonance imaging of the head performed (1.5T Intera, Philips
Medical Systems, Eindhoven, the Netherlands). Sagittal and transverse
plane T2-weighted turbo-spin echo (T2W TSE), fluid attenuated inver-
sion recovery (FLAIR), transverse plane T2* gradient echo, and sagittal
and transverse T1-weighted (T1W TSE) images were acquired before
and after IV injection of gadolinium contrast (0.1 mM/kg gadobutrol;
Bayer plc, Strawberry Hill, UK). Imaging identified a focal, well-demar-
cated, cystic caudal fossa lesion ventral to the cerebellum on the left
side of the fourth ventricle. The lesion was T2W hyperintense com-
pared to normal gray matter (isointense to cerebrospinal fluid), T1W
hypointense compared to normal gray matter and FLAIR attenuating
with no contrast enhancement. The lesion created a mass effect with
compression of the left cerebellar hemisphere and vermis, and a mild
dorsal compression of the left side of the medulla oblongata. No other
abnormalities were detected. The lesion was considered unrelated to
the presumed forebrain localization and an epithelial or ependymal
cyst was considered most likely (Figure 1). No clinical signs attribut-
able solely to a compressive lesion at this site had been observed. The
dog was treated with phenobarbital at 3 mg/kg PO q12h and subse-
quently levetiracetam at 20 mg/kg PO q8h, which later was increased
to 30 mg/kg PO q8h because of a cluster of seizures 8 weeks later.
Serum phenobarbital concentration was monitored and the dosage of
phenobarbital titrated in accordance with physiological weight gain,
achieving a therapeutic concentration (73.3 μM/L; reference range,
65-194 μM/L) at a dosage of 3.5 mg/kg PO q12h, without any appar-
ent improvement in seizure control.
At 6 months of age, the dog was presented again during a facial
twitching episode. These events had still been occurring intermittently
(approximately every 2 weeks) since 3 months of age despite
antiepileptic treatment and progressed to truncal and limb twitching,
also with occasional generalized tonic episodes. Episodes occurred at
any time of day but often overnight, and the dog was otherwise nor-
mal. At this time, the dog was documented to be markedly hypoglyce-
mic (29-45 mg/dL; reference range, 76-119 mg/dL) during 2 days of
hospitalization. Clinical signs resolved immediately after IV administra-
tion of 0.25 g/kg dextrose. The frequency and severity of clinical signs
both were decreased with frequent feeding during hospitalization.
Additional investigations for the cause of hypoglycemia included
an ACTH stimulation test (pre-ACTH plasma concentration of cortisol
0.7 μg/dL and post-ACTH plasma concentration of cortisol 15 μg/dL),
measurement of serum total T4 concentration (11.3 nM/L; reference
range, 10-55 nM/L) and serum thyroid stimulating hormone concen-
tration (0.06 ng/mL; reference range, 0.01-0.6 ng/mL), serum insulin
concentration (41 U/mL; reference range 11.6-29 U/mL) with concur-
rent blood glucose concentration of 54 mg/dL (Alphatrack 2) and
58 mg/dL (fluoride oxalate sample; external laboratory reference
range, 63-108 mg/dL) and serum IGF-1 concentration of 472 μg/L
(reference ranges: dwarfism, <50 μg/L, acromegaly, >1000 μg/L).
Urine culture yielded no growth. Serum fructosamine concentration
was not measured.
The dog was treated with diazoxide (Eudamine, RPH Pharmaceu-
ticals, Jordbro, Sweden) at a dosage of 3.5 mg/kg PO q8h. Feeding
also was divided into 3 to 4 meals per day, using Royal Canin diabetic
diet (Royal Canin, Gard, France) to minimize postprandial insulin
surges. No clinically relevant abnormalities were found on arterial and
venous phase computed tomography imaging of the abdomen and
thorax (16-slice CT scanner [General Electric Medical Systems,
Lightspeed, Chicago, Illinois] and power injector [Empower CTA, Acist
Medical Systems, Eden Prairie, Minnesota]). Levetiracetam treatment
was discontinued and phenobarbital was tapered over 9 weeks and
then discontinued. The dog was neutered at 8 months of age because
testosterone may increase insulin sensitivity,1,2 but no clinical benefit
was appreciated after the procedure.
The dog's clinical signs initially were controlled (mild facial
twitching episodes once every few weeks) when receiving 4.5 mg/kg
diazoxide PO q12h and twice daily feeding. An orally administered
glucose supplement (Glucostop, British Biocell International, UK) was
F IGURE 1 T2-weighted sagittal (A)
and T1-weighted, transverse (at the level
of the caudal medulla oblongata),
postcontrast (B) magnetic resonance
images. A focal, cystic lesion (arrow)
creates mild compression of the left
cerebellar hemisphere and vermis. The
lesion is T2W hyperintense compared to
normal gray matter (isointense to
cerebrospinal fluid), and T1W
hypointense with no contrast
enhancement
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utilized when clinical signs of hypoglycemia were observed. Diazoxide
dose adjustments were made as the dog gained weight with maturity,
and in response to clinical signs. At 18 months of age, imaging was
repeated, and exploratory surgery with pancreatic biopsy was dis-
cussed but not pursued. No abnormalities were detected on repeated
arterial and venous phase contrast CT imaging (320-slice CT scanner
[Canon Medical Systems, Aquilion ONE Genesis Edition, Tochigi,
Japan] and power injector [Bayer plc, Medrad Stellant, Leverkusen,
Germany]. FreeStyle Libre (Abbot Laboratories Limited, UK) interstitial
glucose recording at this time documented average daily blood glu-
cose concentrations of 74 to 110 mg/dL, during a period when the
dog had seizure episodes approximately biannually (focal or general-
ized), on a diazoxide dosage of 5.5 mg/kg PO q12h and consequently
this dose was maintained. The dog's growth, conditioning, and muscle
mass remained normal.
A transient inability to obtain diazoxide resulted in transition to
prednisolone (0.5 mg/kg PO q12h) for a period of 3 weeks. During
this time, a repeat 24-hour blood glucose curve documented blood
glucose concentrations of 50 to 88 mg/dL in addition to subdued
demeanor attributed to hypoglycemia. The dog also was poorly toler-
ant of the glucocorticoid treatment, with polyphagia, polyuria and
polydipsia, and a 1 kg weight loss. Diazoxide was reinstituted and the
dog remains clinically normal on 5.5 mg/kg PO q12h of diazoxide, at
3 years of age. Rare seizures are observed approximately twice per
year (focal or generalized) after exertion, and with or without vomiting
of a diazoxide dose.
2 | DISCUSSION
We describe the presentation and management of a juvenile dog with
hyperinsulinemic hypoglycemic syndrome. Although neither
genotyping nor pancreatic histopathological evaluation was available,
the signalment, investigations performed and stability on medical
treatment over 2 years are inconsistent with insulinoma, and parallel a
diazoxide-responsive form of the syndrome of congenital hyperinsu-
linism (CHI) in people.
A clinical diagnosis of insulinoma requires documentation of
hyperinsulinemia with hypoglycemia, imaging of the pancreas, and
often surgical exploration if abdominal imaging does not identify a
focal pancreatic lesion.3 Considering signalment and history, the index
of suspicion usually is high enough for a neoplastic process that surgi-
cal exploration, intraoperative imaging and partial pancreatectomy are
warranted, with histopathology used as a confirmatory test. Com-
puted tomography has been reported to have a sensitivity of 71% for
identifying pancreatic insulinomas4 and dual phase contrast CT now is
recommended5 for increased sensitivity. Repeated dual phase con-
trast CT identified no such abnormalities in this dog, and thus hyperin-
sulinism was presumed to result from a diffuse pancreatopathy.
Furthermore, the previously reported age range of dogs with
insulinoma is 4 to 14 years6,7 and in 50% of cases the disease is
already metastatic at the time of presentation.8 Although survival
times of 2 to 4 years have been reported after combined surgical and
medical management of insulinoma,,8 medical treatment alone is asso-
ciated with significantly shorter median survival times when compared
to surgical and follow-up medical treatment, with the longest reported
survival of a patient receiving medical management only being
549 days.6,9 A diagnosis of insulinoma was excluded based on
absence of nodular pancreatic lesions on 2 CT examinations, signal-
ment and long-term stability without relapse.
In people, hyperinsulinism in infancy can be transient or persis-
tent. Transient causes of hyperinsulinism include being the infant of a
diabetic mother, perinatal stress or asphyxia, erythroblastosis fetalis,
sepsis, and umbilical artery catheter placement. Hyperinsulinism in
these situations tends to resolve within days to weeks.10 A number of
overlapping and outdated terms have been used to describe juvenile,
persistent, hyperinsulinemic hypoglycemia, such as nesidioblastosis
(also used to describe an adult-onset phenotype), persistent hyper-
insulinemic hypoglycemia in infancy and idiopathic hypoglycemia of
infancy. Congenital hyperinsulinism is now the preferred term, incor-
porating a growing number of characterized mutations, most often of
genes encoding 2 components of the pancreatic β-cell ATP-sensitive
plasma membrane potassium (KATP) channel: the sulfonylurea recep-
tor 1 (SUR1) and Kir6.2 protein.11 Dysfunctional or absent KATP
activity results in persistent membrane depolarization and insulin
release, unrelated to plasma glucose concentrations. The type of
mutation affects the number or activity of the KATP channels, and
hence some mutations may result in diazoxide-responsive hypoglyce-
mia; the extent of residual channel activity dictating diazoxide respon-
siveness. Some of the more rare mutations alter the intracellular ATP
concentration that induces KATP closure, membrane depolarization,
and insulin release independently of blood glucose concentration.
Congenital hyperinsulinism is the most common cause of persis-
tent hyperinsulinemic hypoglycemia in infants12 and can occur in both
focal and diffuse forms. The focal form lends itself to partial pancrea-
tectomy, but the focal nature is challenging to confirm, requiring
genotyping, fluorine-18 L-3,4-dihydroxyphenylalanine positron emis-
sion tomography,13 intraoperative ultrasonography,14 intraoperative
frozen section histopathology,15 or some combination of these for
confirmation. The diffuse form may require subtotal pancreatectomy
as part of management, but it is infrequently curative.15,16
Diazoxide responsiveness is an important feature used in people
to allow characterization of CHI. Among diazoxide-responsive CHI
patients, a genetic mutation is only identified in 27% to 47% of
patients. Among those with mutations identified, the most common
are KATP channel mutations, GLUD1 mutations (causing glutamate
dehydrogenase dysfunction and hyperinsulinism with
hyperammonemia) and GCK (glucokinase) mutations, with the remain-
der being rare mutations in genes such as HNF4A, HADH, UCP2, and
HNF1A.11,17 Patients without identifiable mutations may experience
spontaneous resolution over time, but the timescale of resolution is
unpredictable.18 This same study suggested that lack of an identifiable
genetic mutation and a response to diazoxide are associated with dis-
ease remission.
Despite a positive response to diazoxide treatment, insufficient
evidence was available to confirm an etiology in our case. Two cases
COOK ET AL. 3
termed nesidioblastosis have been reported in the veterinary litera-
ture (a 6-year-old cat and a 6-year-old dog).19,20 In these cases, adult-
onset hypoglycemia resolved with partial pancreatectomy in a dog,
and pancreatic histopathology disclosed diffusely increased islet area
in the pancreas without evidence of malignancy and multifocal micro-
nodular hyperplasia of endocrine and exocrine tissue in a cat. Both
cases were managed successfully by partial pancreatectomy.
Infectious diseases, such as bartonellosis and babesiosis, have
been reported as causes of hyperinsulinemic hypoglycemia in dogs.
The dog of our report was not tested for these diseases because of
systemic stability and a low index of clinical suspicion.21,22 Other dif-
ferential diagnoses excluded or considered unlikely were growth hor-
mone deficiency (based on normal growth and a normal serum IGF-1
concentration), glycogen storage diseases (type 1 [von Gierke's dis-
ease] or type III [Cori's disease]),23 and hyperketotic hypoglycemia.
These glycogen storage diseases would tend to manifest with a more
severe and progressive clinical picture, including weakness, failure to
thrive, exercise intolerance, and hepatopathy.24-26 Hyperketotic hypo-
glycemia encompasses several etiologies including an idiopathic
form.27 Although β-hydroxybutyrate was not measured, no acidosis
suggestive of marked ketonemia was documented and no ketonuria
was observed. Hyperammonemia hypoglycemia syndrome, caused by
a glutamate dehydrogenase mutation, was considered but deemed
unlikely based on normal plasma ammonia concentration during initial
clinical investigations. Congenital glucagon deficiency is poorly
described but tends to be associated with normal insulin concentra-
tions and normal insulin regulation.28,29 In patients with CHI, produc-
tion of glucagon in response to hypoglycemia appears to be
blunted,30 but the capacity for primary glucagon deficiency to cause
hypoglycemia in the face of intact hypothalamic-pituitary-adrenal and
sympathetic adrenomedullary axes is debated.31,32 Counter-regulatory
hormone release and antagonism of insulin activity likely explain
rebound normoglycemia on presentation on multiple occasions in our
dog.33
Diazoxide is a thiazide drug with vasodilatory (and therefore anti-
hypertensive) properties but without diuretic activity. It inhibits pan-
creatic insulin secretion by binding to the SUR1 subunit of β-cell
KATP channels and activating (opening) them, limiting intracellular cal-
cium-mediated insulin release, thereby promoting hyperglycemia.34
Recognized adverse effects include inappetence. Long-term use has
not been specifically reported, but the dog described here appears to
have been tolerant for 2 years without ongoing clinical signs beyond
initial, transient inappetence. Dosing is recommended at 3.3 mg/
kg PO q8h up to 20 to 30 mg/kg PO q8h.35,36 Consideration also
could be given to the use of somatostatin analogues (eg, octreotide) in
the dog of this report, should management of clinical signs prove
problematic in the future, or during any further supply difficulties.37
3 | SUMMARY
Although a relatively novel and extremely rare disease, CHI (of multi-
ple etiologies) is a differential diagnosis for persistently hypoglycemic
juvenile dogs, and even may be considered in normoglycemic patients
with a history of seizures as evidenced by our dog and the dog of pre-
vious case report.19 Medical management with diazoxide has proven
successful thus far, but surgical management and even spontaneous
disease remission both remain possibilities. The affected dog appears
to have a good midrange to long-term prognosis.
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